ERBB2 and breast cancer: Since our findings indicate that ganetespib induces the degradation of ErbB2 in ErbB2+ breast cancer cells (Fig. 5), we aimed to determine whether ErbB2-overexpressing cancer cells are more sensitive to ganetespib than ErbB2-negative cells.